ASCO 2025

ASCO 2025 Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025 Donwload Press release (PDF)

Presentation

Transgene in a nutshell Download(PDF)   Corporate Presentation Download(PDF)   Universal Registration Document Download(PDF)

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2025 Transgene - All rights reserved
Credits